Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-17T13:10:20.506Z Has data issue: false hasContentIssue false
  • English
  • Français

Panic disorder — acceptance of the diagnostic entity and treatment modalities preferred by German health professionals

Published online by Cambridge University Press:  16 April 2020

B Bandelow ,
M Röthemeyer ,
K Sievert ,
G Hajak  and
E Rüther
B Bandelow
Affiliation:
Department of Psychiatry, University of Göttingen, von-Siebold-Str 5,D-37075Göttingen, Germany
M Röthemeyer
Affiliation:
Department of Psychiatry, University of Göttingen, von-Siebold-Str 5,D-37075Göttingen, Germany
K Sievert
Affiliation:
Department of Psychiatry, University of Göttingen, von-Siebold-Str 5,D-37075Göttingen, Germany
G Hajak
Affiliation:
Department of Psychiatry, University of Göttingen, von-Siebold-Str 5,D-37075Göttingen, Germany
E Rüther
Affiliation:
Department of Psychiatry, University of Göttingen, von-Siebold-Str 5,D-37075Göttingen, Germany
Get access

Summary

A survey of the pharmacological and psychological treatment of panic disorder and agoraphobia (PDA) was conducted among 103 physicians, psychologists and psychotherapists. It revealed that the treatments for PDA preferred by the majority of the respondents are inconsistent with the recommendations given in the international literature. Non-psychiatric physicians most frequently proposed herbal preparations as a possible treatment (46% of non-psychiatric physicians), followed by homoeopathic formulations (32%). Tricyclic antidepressants which are recommended as first-line treatment in panic disorder by the literature are preferred by 74% of the psychiatrists, but only by 24% of the non-psychiatric physicians. Benzodiazepines are prescribed by twice as many psychiatrists (45%) as non-psychiatric physicians (22%). Beta blockers and neuroleptics which are not recommended as first-line treatment in panic disorder are used quite often (psychiatrists: 15%; non-psychiatric physicians: 26%). Selective serotonin reuptake inhibitors are prescribed by 24% of the psychiatrists, but by only 3% of the non-psychiatric physicians. Among psychological therapies, psychoanalysis was proposed as first-line treatment by 44% of all professionals applying psychological therapies, while cognitive/behaviour therapy was preferred by only 28%, though proof of efficacy exists only for cognitive/behaviour therapy. In general, psychologists prefer behaviourally-orientated therapy, while physicians mostly propose psychodynamic therapy. One reason for the fact that the results of controlled studies have little influence on professionals treating PDA patients might be that 40% of the respondents do not accept the new classification of the anxiety disorders as introduced in 1980 by the DSM-III.

Keywords

panic disorderagoraphobiadrug treatmentpsychological treatment
Type
Original article
Information
European Psychiatry , Volume 11 , Issue 6 , 1996 , pp. 298 - 305
Copyright
Copyright © Elsevier, Paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adler, ADer Sinn des Lebens MunichBergmann 1933Google Scholar
American Psychiatrie Association Diagnostic and Statistical Manual of Mental Disorders 3rd ed. Washington, DCAmerican Psychiatric Press 1980Google Scholar
American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 3rd ed revised Washington, DCAmerican Psychiatric Press 1987Google Scholar
Aronson, TA, Logue, CMPhenomenology of panic attacks: a descriptive study of panic disorder patients’ self-reports J Clin Psychiatr 1988 49 8–13Google ScholarPubMed
Ballenger, JC, Burrows, GD, DuPont, RL, et al.Alprazolam in panic disorder and agoraphobia: results from a multicenter trial Arch Gen Psychiatry 1988 45 413–422CrossRefGoogle ScholarPubMed
Ballenger, JCOverview of the pharmacotherapy of panic disorderWolfe, BEMaser, JDTreatment of PanicDisorder. A Consensus Development Conference Washington, DCAmerican Psychiatric Press 1994 59–72Google Scholar
Bandelow, B, Sievert, K, Rothemeyer, M, Hajak, G, Rüther, EWhat treatments do patients with panic disorder and agoraphobia get? Eur Arch Psychiatry Clin Neurosci 1995 245 165–171CrossRefGoogle ScholarPubMed
Barlow, DHEffectiveness of behavior treatment for panic disorder with and without agoraphobia In Wolfe, BE, Maser, JDTreatment of Panic Disorder. A Consensus Development Conference Washington, DCAmerican Psychiatric Press 1994 105–120Google Scholar
Black, DW, Wesner, R, Bowers, W, Gabel, JA comparison of fluvoxamine. cognitive therapy, and placebo treatment of panic disorder Arch Gen Psychiatry 1993 50 44–50CrossRefGoogle ScholarPubMed
Bolay, VMusiktherapieCorsini, RHandbuch der Psychotherapie MunichPsychologie-Verlags-Union 1983 729–754Google Scholar
Breier, A, Charney, DS, Heninger, GRAgoraphobia with panic attacks Arch Gen Psychiatry 1986 43 1029–1036CrossRefGoogle ScholarPubMed
Breier, A, Charney, DS, Heninger, GRAgoraphobia with panic attacks Arch Gen Psychiatry 43 1986 1029–1036CrossRefGoogle ScholarPubMed
Clark, DMCognitive therapy for panic disorderWolfe, BEMaser, JDTreatment of Panic Disorder. A Consensus Development Conference Washington, DCAmerican Psychiatric Press 1994 121–132Google Scholar
Clark, DM, Salkovskis, PM, Hackmann, A, Middleton, H, Anastasiades, P, Gelder, MA comparison of cognitive therapy. applied relaxation and imipramine in the treatment of panic disorder Br J Psychiatry 1994 164 759–769CrossRefGoogle ScholarPubMed
Cross-National Collaborative Panic Study/CNCPS Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo Br J Psychiatry 1992 60 191–202Google Scholar
Duggan, DTanztherapieCorsini, RHandbuch der Psychotherapie MunichPsychologie-Verlags-Union 1983 1256–1271Google Scholar
Goisman, RM, Warshaw, MG, Peterson, LG, et al.Panic agoraphobia panic disorder. Data from a multicenter anxiety disorders study J Nerv Ment Dis 1994 182 72–79CrossRefGoogle ScholarPubMed
Grawe, K, Donati, R, Bernauer, FPsychotherapie im Wandel Von der Konfession zur Profession GöttingenHogrefe 1994Google Scholar
Hatch, JP, Saito, IGrowth and development of biofeedback: a bibliographic update Biofeedback Selfregul 1990 15 37–46CrossRefGoogle ScholarPubMed
Hoffart, A, Martinsen, EWExposure-based integrated vs pure psychodynamic treatment of agoraphobic inpatients Psychotherapy 1990 27 210–218CrossRefGoogle Scholar
Jacobson, EProgressive Relaxation ChicagoUniversity Press 1938Google Scholar
Johnston, DG, Troyer, IE, Whitsett, SFClomipramine treatment of agoraphobic women. An eight-week controlled trial Arch Gen Psychiatry 1988 45 453–459CrossRefGoogle ScholarPubMed
Katon, W, von, Korff, Lin, EPanic disorder: relationship to high medical utilization Am J Med 1992 92supl 1a 7–11CrossRefGoogle ScholarPubMed
Klein, DF, Ross, DC, Cohen, PPanic avoidance in agoraphobia. Application of path analysis to treatment studies Arch Gen Psychiatry 1987 44 377–385CrossRefGoogle ScholarPubMed
Klein, DFAnxiety reconceptualized. Gleaning from pharmacological dissection —early experience with imipramine and anxiety Mod Probl Pharmacopsychiatry 1987 22 1–35CrossRefGoogle ScholarPubMed
Klosko, JS, Barlow, DH, Tassinari, R, Cerny, JAA comparison of alprazolam and behavior therapy in treatment of panic disorder J Consult Clin Psychol 1990 58 77–84CrossRefGoogle ScholarPubMed
Laakmann, G, Blaschke, D, Eissner, HJ, Hippius, HNiedrig dosierte Neuroleptika in der Behandlung von Angstzustän-den-Ergebnisse einer AmbulanzstudieHippius, HLaakmann, GTherapie mit Neuroleptika-Niedrigdosierung ErlangenPerimed 1988Google Scholar
Leuner, HKatathymes Bilderleben StuttgartThieme 1981Google Scholar
Levick, MKunsttherapieCorsini, RHandbuch der Psychotherapie MunichPsychologie-Verlags-Union 1983 601–619Google Scholar
Marks, IMFears, Phobias and Rituals New YorkOxford University Press 1987Google Scholar
Marks, IM, Gray, S, Cohen, D, Hill, R, Mawson, D, Ramm, E, Stern, RSImipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework Arch Gen Psychiatry 1983 40 153–162CrossRefGoogle ScholarPubMed
Marks, IM, Swinson, RP, Basoglu, M, et al.Alprazolam exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto Br J Psychiatry 1993 162 776–787CrossRefGoogle ScholarPubMed
Mavissakalian, M, Michelson, LAgoraphobia: relative and combined effectiveness of the-rapist-assisted in vivo exposure and imipramine J Clin Psychiatry 1986 47 117–122Google ScholarPubMed
Mavissakalian, M, Michelson, LTwo-year follow-up exposure and imipramine treatment of agoraphobia Am J Psychiatry 1986 143 1106–1112Google ScholarPubMed
Munjack, DJ, Crocker, B, Cabe, D, et al.Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks J Clin Psychopharmacol 1989 9 22–27CrossRefGoogle ScholarPubMed
National Institute of Health NIH Consensus Development Conference Statement Vol 9 No 2 Treatment of Panic Disorder Bethesda, MDNIH 1991Google Scholar
Ravaris, CL, Friedman, MJ, Hauri, PJ, McHugo, GJA control-led study of alprazolam and propranolol in panic disorder and agoraphobia J Clin Psychopharmacol 1991 11 344–350CrossRefGoogle Scholar
Regier, DA, Boyd, JH, Burke, JD, et al.One-month prevalence of mental disorders in the United States: Based on five epidemiologic catchment area sites Arch Gen Psychiatry 1988 45 977–986CrossRefGoogle ScholarPubMed
Rogers, CRClient-Centered Psychotherapy BostonHoughton Mifflin 1951Google Scholar
Rosenberg, R, Ottosson, JO, Bech, P, Mellergård, M, Rosenberg, NKValidation criteria for panic disorder as a nosological entity Acta Psychiatr Stand 1991 365suppl 7–17CrossRefGoogle ScholarPubMed
Satoh, K, Fujii, ICurrent views on panic disorder and its management in Japan: a national survey Jpn J Psychiatr Neural 1992 46 45–53Google ScholarPubMed
Schultz, HJDas Autogene Training 18th edn. StuttgartThieme 1987Google Scholar
Sheehan, DV, Ballenger, J, Jacobsen, GTreatment of endogenous anxiety with phobic, hysterical, and hypochondiral symptoms Arch Gen Psychiatry 1980 37 51–59CrossRefGoogle ScholarPubMed
Swinson, RP, Cox, BJ, Woszczyna, CBUse of medical services and treatment for panic disorder with agoraphobia and for social phobia Can Med Assoc J 1992 147 878–883Google ScholarPubMed
Taylor, CB, King, R, Margraf, J, Ehlers, A, Telch, M, Roth, WT, Agras, WSUse of medication and in vivo exposure in volunteers for panic disorder research Am J Psychiatry 1989 146 1423–1426Google ScholarPubMed
Telch, MJ, Agras, WS, Taylor, CB, Roth, WT, Gallen, CCCombined pharmacological and behavioral treatment for agoraphobia Behav Res Ther 1985 23 325–335CrossRefGoogle ScholarPubMed
Wolpe, JPsychotherapy by Reciprocal Inhibition Stanford, CAStanford University Press 1958Google Scholar
World Health Organization WHO Mental Disorders: Glossary and guide to their Classification in Accordance with the 9th Revision of the International Classification of Diseases GenevaWorld Health Organisation 1978Google Scholar
World Health Organisation WHO (Mental and behavioural disorders including disorders of psychological development) Clinical descriptions and diagnostic guidelines ch 5 (F)10th Revision of the International Classification of Diseases GenevaWorld Health Organisation 1991Google Scholar
Submit a response

Comments

No Comments have been published for this article.